Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal

Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in an agreement worth up to $135 million. Dongbao will have rights to BioChaperone^® Combo, a fixed-ratio insulin glargine and insulin lispro combination, plus BioChaperone^® Lispro, an ultra-rapid insulin. Adocia's BioChaperone platform uses polymers, oligomers and small organic compounds to protect proteins from degradation. Dongbao already has a portfolio of diabetes treatments. More details....

Stock Symbols: (SHA: 600867) (Paris: ADOC)

Share this with colleagues:

Original Article: Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal

More From BioPortfolio on "Dongbao Pharma Acquires Two Diabetes Treatments in $135 Million Deal"